Sortina Pharma AB announces the appointment of new members to its Board of Directors

Sortina Pharma AB announces the appointment of new members to its Board of Directors, strengthening the company for acceleration and positioning in the development of world leading anti-Sortilin small molecule therapeutics.

Sara Malcus, Catharina Bäärnhielm and Peter Suenaert have all joined the Board of Directors of Sortina Pharma and Sara Malcus takes over the role as Chairman of the Board.

- I am honored to join Sortina as the chair at this significant time of acceleration of development of the company´s exciting portfolio of therapeutic targets. I see great potential in the anti-sortilin approach taken by Sortina and I look forward to being part of their journey ahead, says Sara Malcus

Sara Malcus, PhD has extensive experience from life science, – and business development and has over the past 15 years held several executive management and board positions in drug developing start-up companies. Sara has been involved in numerous pre-clinical and clinical collaborations between the industry and academia and has also been part of the AstraZeneca global partnering team.

Catharina Bäärnhielm, PhD has almost 40 years’ experience from a variety of senior positions at AstraZeneca, from early preclinical, through clinical and to marketing. Catharina has a broad experience as board member in several biotech companies as well as GU Ventures.

Peter Suenaert, PhD, MD has about 30 years of clinical-scientific experience, i.e. first in clinical practice and subsequently for more than 15 years in global clinical development within the oncology therapeutic area in the pharmaceutical and biotech industry. Peter is driven by the passion for science and its translation into benefit of patients and, since 2007, he has been leading and/or contributing to the development of several (immuno-)oncology agents from conception to regulatory pivotal stage in progressively responsible global development positions. 

- Over the last 3 years we have developed a strong portfolio of novel chemical structures and built a pipeline addressing several of the world toughest health challenges with our main focus within cancer. As we mature and strengthen our position within the Sortilin therapeutic areas we are pleased to welcome Sara Malcus, Catharina Bäärnhielm and Peter Suenaert to our Board of Directors. This signifies an important step in company growth and our core commitment towards further advances in development of novel treatment options for the most aggressive and non-treatable cancers, says Sara Rhost, co-founder and CEO of Sortina Pharma.

For more information, please contact:

Sara Rhost, CEO, sararhost@sortinapharma.com